Immuneonco Biopharmaceutical Inc. (R9Z)

Overview

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through the development of innovative immuno-oncology therapies. Founded in 2015 and based in Shanghai, China, the company has quickly established itself as a leader in the field of cancer immunotherapy. ImmuneOnco's research and development efforts are focused on creating targeted therapies that harness the body's immune system to fight cancer more effectively. With a robust pipeline of product candidates, the company is addressing a wide range of cancers including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), colorectal cancer (CRC), B-cell non-Hodgkin lymphoma (B-NHL), and various solid tumors.

Products and Services

• IMM01: A clinical-stage CD47-targeted molecule designed for the treatment of a wide range of cancers including MDS, AML, CMML, cHL, NSCLC, SCLC, HNSCC, and CRC. IMM01 works by targeting CD47, a protein that cancer cells exploit to avoid being destroyed by the immune system.
• IMM0306: A CD47×CD20 bispecific molecule under development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). By simultaneously targeting CD47 and CD20, IMM0306 aims to enhance the immune response against cancer cells.
• IMM2902: A CD47×HER2 bispecific molecule geared towards the treatment of HER2-positive and HER2-low expressing solid tumors. IMM2902 seeks to leverage the dual targeting of CD47 and HER2 to improve therapeutic outcomes.
• IMM2520: A CD47×PD-L1 bispecific molecule designed for the treatment of solid tumors. This bispecific molecule attempts to block PD-L1 interactions while targeting CD47, potentially enhancing anti-cancer immunity.
• IMM47: A humanized monoclonal antibody that targets CD24 for cancer treatment. CD24 is another checkpoint that cancer cells use to escape immune surveillance, and IMM47 aims to neutralize this escape mechanism.
• IMM4701: A bispecific molecule that simultaneously targets CD47 and CD24. By attacking two escape mechanisms at once, IMM4701 could offer a potent therapeutic approach against cancer.
• IMM2510: A bispecific molecule featuring a mAb-Trap structure that targets VEGF and PD-L1. This innovative approach is designed to cut off the tumor's blood supply while inhibiting its ability to evade immune detection.
• IMM27M: A CTLA-4 antibody enhanced with ADCC (Antibody-Dependent Cellular Cytotoxicity) activity. Targeting CTLA-4, a critical immune checkpoint, IMM27M is aimed at bolstering the immune system's response to cancer cells.
• IMM40H: A humanized IgG1 CD70 monoclonal antibody with enhanced ADCC activity. By targeting CD70, IMM40H is designed to stimulate a robust immune response against cancer cells.